Does ERG Expression Predict Docetaxel Benefit in Prostate Cancer?
Tumor expression of the oncogene ERG might predict patient benefit from adding docetaxel to androgen deprivation therapy (ADT), according to... Read More
Addressing Physical, Cognitive Effects of ADT in Prostate Cancer Patients
At this year’s American Society of Clinical Oncology (ASCO) Annual meeting, Alicia K. Morgans, MD, assistant professor of medicine in... Read More
Prostate Cancer Molecular Subtyping Groups Tumors by Prognosis, Response
Molecular subtyping of prostate cancer into three categories—luminal A, luminal B, and basal—identifies differences in prognosis and response to treatment,... Read More
Urinary RNA Testing Could Avoid Unnecessary Prostate Biopsies
Combined urinary testing for PCA3 and TMPRSS2:ERG (T2:ERG) RNA can help avoid unnecessary biopsies while maintaining ability to detect aggressive... Read More
AUA: Prostate Cancer Surveillance Yields Good Results in Younger Patients
Active surveillance can yield excellent results in carefully selected younger men with prostate cancer, according to a new study. A... Read More
Custirsen Does Not Improve Overall Survival in mCRPC
The addition of custirsen to docetaxel and prednisone failed to improve overall survival among patients with metastatic castration-resistant prostate cancer... Read More
Testosterone Replacement Linked to Lower Rates of Aggressive Prostate Cancer
Men who receive testosterone replacement therapy (TRT) had an increased rate of favorable-risk prostate cancer compared to those who did... Read More
Liquid Biopsy Shows Promise in Advanced Prostate Cancer
“Liquid biopsy” analyses of circulating tumor DNA (ctDNA) from blood samples potentially reveal prognostic information about metastatic castration-resistant prostate cancer... Read More
Photodynamic Therapy Can Preserve Tissue in Low-Risk Prostate Cancer
Vascular-targeted photodynamic therapy with padeliporfin was significantly better than active surveillance over a 2-year period in men with low-risk localized... Read More
No Prostate Cancer Mortality Benefit With PSA Screening
Long-term follow-up of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) confirmed earlier results showing no reduction in... Read More